Home » Stocks » GRFS

Grifols S.A. (GRFS)

Stock Price: $19.08 USD 0.00 (0.00%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 17.49B
Revenue (ttm) 5.73B
Net Income (ttm) 702.41M
Shares Out 687.55M
EPS (ttm) 0.60
PE Ratio 31.83
Forward PE 12.85
Dividend $0.42
Dividend Yield 2.20%
Trading Day January 15
Last Price $19.08
Previous Close $19.08
Change ($) 0.00
Change (%) 0.00%
Day's Open 19.20
Day's Range 19.08 - 19.30
Day's Volume 761,360
52-Week Range 15.39 - 25.62

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 19 hours ago

BARCELONA, Spain, Jan. 18, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record o...

Zacks Investment Research - 6 days ago

GRFS vs. ZTS: Which Stock Is the Better Value Option?

Other stocks mentioned: ZTS
Seeking Alpha - 2 weeks ago

Good prospects for the global immunoglobulin business. Koru Medical's strategic plan is to reach $ 50M in sales by 2022, a gross margin of 70%, and organic and annual sales growth of + 20%.

Zacks Investment Research - 1 month ago

Let's see if Grifols (GRFS) stock is a good choice for value-oriented investors right now from multiple angles.

PRNewsWire - 2 months ago

BARCELONA, Spain, Nov. 16, 2020 /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and one of the world's leading producers of plasma-derived medicines...

PRNewsWire - 2 months ago

BARCELONA, Spain, Nov. 12, 2020 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and provider of technologies and se...

Seeking Alpha - 2 months ago

Oligopoly of four companies that control more than 80% of the plasma business. Secular growth trend for population aging.

GuruFocus - 2 months ago

Fund boosts holding in Buffett's conglomerate, announces management changes

Other stocks mentioned: ROST, BRK.A, BRK.B, HLFFF, IDEXY
Zacks Investment Research - 2 months ago

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

Other stocks mentioned: CI, CWBR, DRRX, PTI
Seeking Alpha - 2 months ago

The Spanish market has gotten crushed with an uptick in COVID-19 deaths. Grifols stock is about where it was when I visited headquarters three years ago.

Zacks Investment Research - 2 months ago

GRFS vs. ZTS: Which Stock Is the Better Value Option?

Other stocks mentioned: ZTS
PRNewsWire - 3 months ago

BARCELONA, Spain, Oct. 9, 2020 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of...

PRNewsWire - 3 months ago

- The investment includes a fractionation plant with a 1.5 million-liter annual capacity and two purification plants, making Grifols the only large-scale commercial manufacturer of plasma prod...

GuruFocus - 3 months ago

According to the GuruFocus All-in-One Screener, a Premium feature, as of Sept. 30 the following guru-held companies have positive future earnings estimates from Morningstar analysts.

Other stocks mentioned: BXP, CBRE, ESS, KR
GuruFocus - 3 months ago

According to the GuruFocus All-in-One Screener, a Premium feature, the following companies have high business predictability ratings and wide margins of safety as of Sept. 28.

Other stocks mentioned: ACGL, AMP, BXP, MLM
Benzinga - 4 months ago

Blood plasma and diagnostics company Grifols SA (NASDAQ: GRFS) is set to completely acquire Alkahest Inc, a biopharmaceutical startup focussed on neurodegenerative and age-related diseases, fo...

PRNewsWire - 4 months ago

BARCELONA, Spain, and SAN CARLOS, Calif., Sept. 7, 2020 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the ...

Benzinga - 4 months ago

Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use ...

Other stocks mentioned: ADMA, CERS, KMDA, LMNL, SONN, THMO, TTOO
The Motley Fool - 5 months ago

The results provide more justification for the FDA to grant the substance emergency use authorization.

Other stocks mentioned: TAK
PRNewsWire - 5 months ago

BARCELONA, July 28, 2020 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more ...

PRNewsWire - 5 months ago

- Grifols makes a significant investment to become the only large-scale commercial manufacturer of plasma products in Canada, with a fractionation capacity of 1.5 million liters/year - The ope...

GuruFocus - 6 months ago

The following companies have grown their earnings per share over a five-year period.

Other stocks mentioned: BIIB, CBPO, HCA, UHS
The Motley Fool - 6 months ago

Each company has a triad of COVID-19 projects, but they aren't in direct competition.

Other stocks mentioned: NVS
The Motley Fool - 7 months ago

Antibodies of recovered patients can help treat people who are infected with the novel coronavirus.

Other stocks mentioned: EBS, TAK
InvestorPlace - 7 months ago

Much of the conversation about pharmaceutical stocks rests on the coronavirus, but these high-growth names have potential beyond the pandemic.

Other stocks mentioned: JNJ, MRK, RDY, RGEN, TAK, ZTS
Investors Business Daily - 8 months ago

Pharmaceutical stocks dipped by a double-digit percentage in the first four months of 2020, trailing their biotech brethren. Still, there are standout companies in the industry group.

Other stocks mentioned: ABBV, AGN, BMY, JAZZ, MRK, NVO, SNY, ZTS
Zacks Investment Research - 8 months ago

GRFS vs. ZTS: Which Stock Is the Better Value Option?

Other stocks mentioned: ZTS
Zacks Investment Research - 9 months ago

Grifols (GRFS) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.

Benzinga - 9 months ago

Grifols (NASDAQ: GRFS) shares are trading higher on Thursday. The company announced it's working with the U.S.

Zacks Investment Research - 10 months ago

Grifols (GRFS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 10 months ago

GRFS vs. IONS: Which Stock Is the Better Value Option?

Other stocks mentioned: IONS
Zacks Investment Research - 11 months ago

GRFS vs. IONS: Which Stock Is the Better Value Option?

Other stocks mentioned: IONS
Investors Business Daily - 1 year ago

Shares of Grifols popped in massive volume Friday after the Spain-based pharmaceutical company gained Food and Drug Administration approval for an immunodeficiency treatment.

Zacks Investment Research - 1 year ago

GRFS vs. ORINY: Which Stock Is the Better Value Option?

About GRFS

Grifols, S.A. develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates in five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. It offers intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic... [Read more...]

Industry
Drug Manufacturers-General
IPO Date
May 17, 2006
CEO
Raimon Grifols Roura
Employees
24,000
Stock Exchange
NASDAQ
Ticker Symbol
GRFS
Full Company Profile

Financial Performance

In 2019, Grifols S.A.'s revenue was 5.10 billion, an increase of 13.64% compared to the previous year's 4.49 billion. Earnings were 625.15 million, an increase of 4.78%.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Grifols S.A. stock is "Buy." The 12-month stock price forecast is 32.10, which is an increase of 68.24% from the latest price.

Price Target
$32.10
(68.24% upside)
Analyst Consensus: Buy